MSMB: Difference between revisions
No edit summary |
|||
Line 9: | Line 9: | ||
== Clinical significance == |
== Clinical significance == |
||
Two large genome wide association studies showed that decreased expression of the MSMB protein caused by the rs10993994 [[single nucleotide polymorphism]] is associated with an increased risk of developing prostate cancer (odds ratio for CT allele pair ~1.2x, and for TT allele pair ~1.6x when compared to the low risk CC allele pair)<ref>{{cite journal|last=Thomas|first=G|title=Multiple loci identified in a genome-wide association study of prostate cancer|journal=Nat Genet|year=2008|pmid=18264096}}</ref><ref>{{cite journal|last=Eeles|first=R.A.|title=Multiple newly identified loci associated with prostate cancer susceptibility|journal=Nat Genet|year=2008|pmid=18264097}}</ref>. A 2003 study proposed using a truncated form of MSMB called PSP61 as a biomarker for [[benign prostatic hyperplasia]] |
Two large genome wide association studies showed that decreased expression of the MSMB protein caused by the rs10993994 [[single nucleotide polymorphism]] is associated with an increased risk of developing prostate cancer (odds ratio for CT allele pair ~1.2x, and for TT allele pair ~1.6x when compared to the low risk CC allele pair)<ref>{{cite journal|last=Thomas|first=G|title=Multiple loci identified in a genome-wide association study of prostate cancer|journal=Nat Genet|year=2008|pmid=18264096}}</ref><ref>{{cite journal|last=Eeles|first=R.A.|title=Multiple newly identified loci associated with prostate cancer susceptibility|journal=Nat Genet|year=2008|pmid=18264097}}</ref>. A 2003 study proposed using a truncated form of MSMB called PSP61 as a biomarker for [[benign prostatic hyperplasia]]: this study found PSP61 in the expressed prostatic secretion of 10 out of ten 10 men suffering from BPH, but did not find it in 10 out of 10 aged matched BPH free men<ref>{{cite journal|last=Xu|first=K|title=Identification of a specifically expressed modified form of novel PSP-94 protein in the secretion of benign prostatic hyperplasia|journal=Electrophoresis|year=2003|pmid=12707925}}</ref>. |
||
The expression of beta-microseminoprotein is found to be decreased in [[prostate cancer]]; urinary MSMB has been found to be superior than urinary [[prostate-specific antigen|PSA]] at differentiating men with prostate cancer at all [[Gleason Grading System|Gleason grades]].<ref name="Whitaker_2010">{{cite journal | author = Whitaker HC | title = The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine | journal = PLoS ONE | year = 2010 | volume = 5 | issue = 10 | pages = e13363 | doi = 10.1371/journal.pone.0013363 | author-separator = , | author2 = Kote-Jarai Z | author3 = Ross-Adams H | author4 = Warren AY | author5 = Burge J | display-authors = 5 | editor1-last = Vickers | editor1-first = Andrew | last6 = George | first6 = Anne | last7 = Bancroft | first7 = Elizabeth | last8 = Jhavar | first8 = Sameer | last9 = Leongamornlert | first9 = Daniel | pmid = 20967219 | pmc = 2954177 }}</ref> |
The expression of beta-microseminoprotein is found to be decreased in [[prostate cancer]]; urinary MSMB has been found to be superior than urinary [[prostate-specific antigen|PSA]] at differentiating men with prostate cancer at all [[Gleason Grading System|Gleason grades]].<ref name="Whitaker_2010">{{cite journal | author = Whitaker HC | title = The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine | journal = PLoS ONE | year = 2010 | volume = 5 | issue = 10 | pages = e13363 | doi = 10.1371/journal.pone.0013363 | author-separator = , | author2 = Kote-Jarai Z | author3 = Ross-Adams H | author4 = Warren AY | author5 = Burge J | display-authors = 5 | editor1-last = Vickers | editor1-first = Andrew | last6 = George | first6 = Anne | last7 = Bancroft | first7 = Elizabeth | last8 = Jhavar | first8 = Sameer | last9 = Leongamornlert | first9 = Daniel | pmid = 20967219 | pmc = 2954177 }}</ref> |
||
Revision as of 20:10, 4 January 2013
Template:PBB Beta-microseminoprotein is a protein that in humans is encoded by the MSMB gene.[1][2]. For historical reasons, the scientific literature refers to this protein as: Prostate secretory protein 94 (PSP94), microseminoprotein (MSP), microseminoprotein-beta (MSMB), beta-inhibitin, prostatic inhibin peptide (PIP), inhibitin like material (ILM).
Function
Beta-microseminoprotein is a member of the immunoglobulin binding factor family. It is synthesized by the epithelial cells of the prostate gland and secreted into the seminal plasma. This protein has inhibin-like activity. It may have a role as an autocrine paracrine factor in uterine, breast and other female reproductive tissues. Two alternatively spliced transcript variants encoding different isoforms are described for this gene. The use of alternate polyadenylation sites has been found for this gene.[2] Beta microseminoprotein is one of the three major proteins secreted by the prostate[3] and has a concentration in seminal plasma of 0.5 to 1 mg/mL.[4] Beta-microseminoprotein is the main component in seminal plasma active against Candida albicans after sexual intercourse.[5] The protein inhibits growth of cancer cells in an experimental model of prostate cancer[6] and is used as a biomarker for prostate cancer.[7]
Clinical significance
Two large genome wide association studies showed that decreased expression of the MSMB protein caused by the rs10993994 single nucleotide polymorphism is associated with an increased risk of developing prostate cancer (odds ratio for CT allele pair ~1.2x, and for TT allele pair ~1.6x when compared to the low risk CC allele pair)[8][9]. A 2003 study proposed using a truncated form of MSMB called PSP61 as a biomarker for benign prostatic hyperplasia: this study found PSP61 in the expressed prostatic secretion of 10 out of ten 10 men suffering from BPH, but did not find it in 10 out of 10 aged matched BPH free men[10]. The expression of beta-microseminoprotein is found to be decreased in prostate cancer; urinary MSMB has been found to be superior than urinary PSA at differentiating men with prostate cancer at all Gleason grades.[11]
References
- ^ Ulvsback M, Spurr NK, Lundwall A (1992). "Assignment of the human gene for beta-microseminoprotein (MSMB) to chromosome 10 and demonstration of related genes in other vertebrates". Genomics. 11 (4): 920–4. doi:10.1016/0888-7543(91)90015-7. PMID 1783399.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ a b "Entrez Gene: MSMB microseminoprotein, beta-".
- ^ Lilja H, Abrahamsson PA (1988). "Three predominant proteins secreted by the human prostate gland". Prostate. 12 (1): 29–38. doi:10.1002/pros.2990120105. PMID 3347596.
- ^ Valtonen-André C, Sävblom C, Fernlund P, Lilja H, Giwercman A, Lundwall A (2008). "Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males". J. Androl. 29 (3): 330–7. doi:10.2164/jandrol.107.003616. PMID 18222915.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Edström Hägerwall AM, Rydengård V, Fernlund P, Mörgelin M, Baumgarten M, Cole AM, Malmsten M, Kragelund BB, Sørensen OE (2012). "β-Microseminoprotein Endows Post Coital Seminal Plasma with Potent Candidacidal Activity by a Calcium- and pH-Dependent Mechanism". PLoS Pathog. 8 (4): e1002625. doi:10.1371/journal.ppat.1002625. PMID 22496651.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) - ^ Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA (2003). "Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer". Cancer Res. 63 (9): 2072–8. PMID 12727822.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE (2010). "The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target". Prostate. 70 (3): 333–40. doi:10.1002/pros.21059. PMID 19790236.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Thomas, G (2008). "Multiple loci identified in a genome-wide association study of prostate cancer". Nat Genet. PMID 18264096.
- ^ Eeles, R.A. (2008). "Multiple newly identified loci associated with prostate cancer susceptibility". Nat Genet. PMID 18264097.
- ^ Xu, K (2003). "Identification of a specifically expressed modified form of novel PSP-94 protein in the secretion of benign prostatic hyperplasia". Electrophoresis. PMID 12707925.
- ^ Whitaker HC; Kote-Jarai Z; Ross-Adams H; Warren AY; Burge J; et al. (2010). Vickers, Andrew (ed.). "The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine". PLoS ONE. 5 (10): e13363. doi:10.1371/journal.pone.0013363. PMC 2954177. PMID 20967219.
{{cite journal}}
: Unknown parameter|author-separator=
ignored (help)CS1 maint: unflagged free DOI (link)